| __timestamp | Neurocrine Biosciences, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 2999000 |
| Thursday, January 1, 2015 | 32480000 | 10393000 |
| Friday, January 1, 2016 | 68081000 | 15994000 |
| Sunday, January 1, 2017 | 169906000 | 26975000 |
| Monday, January 1, 2018 | 248932000 | 39509000 |
| Tuesday, January 1, 2019 | 354100000 | 48869000 |
| Wednesday, January 1, 2020 | 433300000 | 42510000 |
| Friday, January 1, 2021 | 583300000 | 46105000 |
| Saturday, January 1, 2022 | 752700000 | 50513000 |
| Sunday, January 1, 2023 | 887600000 | 51292000 |
| Monday, January 1, 2024 | 1007200000 |
Data in motion
In the competitive landscape of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Neurocrine Biosciences, Inc. has demonstrated a robust increase in Selling, General, and Administrative (SG&A) expenses, growing nearly 50 times from 2014 to 2023. This surge reflects their aggressive expansion and investment in operational capabilities. In contrast, Wave Life Sciences Ltd. has maintained a more conservative growth in SG&A expenses, increasing by approximately 17 times over the same period. This difference highlights distinct strategic approaches: while Neurocrine is scaling rapidly, Wave Life Sciences is focusing on steady, sustainable growth. These trends not only underscore the dynamic nature of the biotech sector but also provide a window into how these companies are positioning themselves for future success.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.